Code | 8029D | ||||||||||
MA number | 44/0154/21-S | ||||||||||
Product Form: | tbl 120x250 mg (fľ.HDPE) | ||||||||||
MA Status: | R - Valid Marketing Authorisation | ||||||||||
Type of procedure: | Decentralised | ||||||||||
MAH, country: | medac Gesellschaft für klinische Spezialpräparate m.b.H., Germany | ||||||||||
Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 30 | ||||||||||
Container: | bottle HDPE | ||||||||||
Route of admin.: | Oral use |
Prescription Status: | Medicinal product subject to medical prescription. |
Legal basis: | Article 10(1) generic application |
MA issued: | 28.07.2021 |
Validity: | 28.07.2026 |
SPC: | SPC_Abiraterone medac 250 mg tablety_07_2021.pdf |
PIL: | PIL_Abiraterone medac 250 mg tablety_04.2022.pdf |
Safety feature | Yes |
Data update: | 10.08.2021 |